SuperworthConexeu Sciences CNXU
- Market cap
- $87.4M
- PE
- n/m
- one or more of the four quarters through 2026-07-31 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| R&D | $23.7K | $42.5K | $134.7K | $62.6K | $66.6K | $270.4K |
| SG&A | $8.5K | $25K | $22.6K | $18.4K | $26.1K | $140.6K |
| −$333.5K | −$457K | −$1.3M | −$1.7M | −$2.4M | −$7.7M | |
| Interest expense | $3.6K | $1.4K | −$43 | $0 | $0 | $0 |
| Pre-tax income | −$290.1K | −$458.1K | −$1.3M | −$1.7M | −$2.3M | −$7.7M |
| $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$290.1K | −$458.1K | −$1.3M | −$1.7M | −$2.3M | −$7.7M |
| −$0.03 | −$0.05 | −$0.09 | −$0.08 | −$0.11 | −$0.29 | |
| 8.9M | 9.5M | 14.1M | 20.6M | 20.6M | 27M |
R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Conexeu Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CNXUConexeu Sciences | $87.4M | n/m | n/a | n/m | n/m | n/m | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $257M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on Conexeu Sciences
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .